
    
      The data will be collected in consecutive subjects treated with the commercially available
      product and following standard clinical practice. This registry will be limited to subjects
      who have received only the CORDIS ENTERPRISEâ„¢ VRD during the index procedure. While only
      limited inclusion or exclusion criteria are specified, uniform, complete and accurate data
      will be collected peri-procedurally, during the index hospitalization, and during follow-up
      up to 6 months. All subjects should be treated according to the Instruction For Use (IFU)
      including conduct of the VRD placement, coiling procedure, application of antiplatelet
      medication and any other medical therapy to be provided according to local usual practice.
    
  